Bosentan — Discount Pricing

Other medications in Heart & Cardiovascular

• Bumetanide
• Candesartan
• Cangrelor
• Captopril
• Carvedilol
• Chlorthalidone
• Cholestyramine
• Colesevelam

About Bosentan

Bosentan is a crucial medication used to treat pulmonary arterial hypertension (PAH), a serious condition affecting the arteries in the lungs. At TheDrugClub, we understand the financial burden of managing chronic illnesses. Discover how our membership can help you access bosentan more affordably, making your health a priority without breaking the bank.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Bosentan is approved for (FDA label)

Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability.

Source: Read the full FDA label on DailyMed. Label effective date: June 2, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Bosentan (FDA label)

WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Bosentan is available only through a restricted distribution program called the Bosentan Risk Evaluation and Mitigation Strategy (REMS) because of the risk of hepatotoxicity ( 5.2 ): Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with bosentan ( 5.1 ). Measure liver aminotransferases prior to initiation of treatment and then monthly ( 2.1 , 5.1 ). Discontinue bosentan if aminotransferase elevations are accompanied by signs or symptoms of liver dysfunction or injury or increases in bilirubin ≥ 2 x ULN ( 2.4 , 5.1 ). Based on animal data, bosentan may cause fetal harm if used during pregnancy ( 4.1 , 5.3 , 8.1 ). Females of reproductive potential: Exclude pregnancy before initiating treatment. Use effective contraception prior to initiation of treatment, during treatment and for one month after stopping bosentan ( 2.1 , 4.1 , 5.3 , 8.1 , 8.3 ). When pregnancy is detected, discontinue bosentan as soon as possible ( 5.3 ). Because of the risk of hepatotoxicity, bosentan is available only through a restricted program called the Bosentan Risk Evaluation and Mitigation Strategy (REMS).

Source: FDA prescribing information (DailyMed). Set ID: 8444da17-6c31-492b-8842-93740f083d9d. SPL document ID: 6f108d08-40d2-4db6-a938-f6c3b54b3e02. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Bosentan (FDA label)

Film-coated Tablet: 62.5 mg and 125 mg ( 3 ) 62.5 mg and 125 mg film-coated, tablets for oral administration. 62.5 mg tablets: Peach to light pink colored, coated, round, biconvex, tablets debossed with '446' on one side and plain on other side. 125 mg tablets: Peach to light pink colored, coated, oval, biconvex, tablets debossed with '447' on one side and plain on other side.

Source: FDA prescribing information (DailyMed). Set ID: 8444da17-6c31-492b-8842-93740f083d9d. SPL document ID: 6f108d08-40d2-4db6-a938-f6c3b54b3e02. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Bosentan (FDA label)

Common adverse reactions (≥ 3% more than placebo) for the film-coated tablet are respiratory tract infection and anemia ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: 8444da17-6c31-492b-8842-93740f083d9d. SPL document ID: 6f108d08-40d2-4db6-a938-f6c3b54b3e02. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Bosentan (FDA label)

Pregnancy ( 4.1 ) Use with Cyclosporine A ( 4.2 ) Use with Glyburide ( 4.3 ) Hypersensitivity ( 4.4 ) 4.1 Pregnancy Use of bosentan is contraindicated in females who are pregnant [see Boxed Warning, Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.3 ), Use in Specific Populations ( 8.1 )]. 4.2 Use with Cyclosporine A Coadministration of cyclosporine A and bosentan resulted in markedly increased plasma concentrations of bosentan. Therefore, concomitant use of bosentan and cyclosporine A is contraindicated [see Drug Interactions ( 7.1) ] . 4.3 Use with Glyburide An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore coadministration of glyburide and bosentan is contraindicated [see Drug Interactions ( 7.1) ] . 4.4 Hypersensitivity Bosentan is contraindicated in patients who are hypersensitive to bosentan or any component of the product.

Source: FDA prescribing information (DailyMed). Set ID: 8444da17-6c31-492b-8842-93740f083d9d. SPL document ID: 6f108d08-40d2-4db6-a938-f6c3b54b3e02. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Bosentan (FDA label)

Fluid retention: May require intervention ( 5.4 ). Pulmonary veno-occlusive disease (PVOD): If signs of pulmonary edema occur, consider the diagnosis of associated PVOD and consider discontinuing bosentan ( 5.5 ). Decreased sperm counts ( 5.6 ). Decreases in hemoglobin and hematocrit: Monitor hemoglobin levels after 1 and 3 months of treatment, then every 3 months thereafter ( 5.7 ). 5.1 Hepatotoxicity ALT or AST > 3 x ULN were observed in 11% of bosentan-treated patients (n = 658) compared to 2% of placebo-treated patients (n = 280). Three-fold increases were seen in 12% of 95 pulmonary arterial hypertension (PAH) patients on 125 mg twice daily and 14% of 70 PAH patients on 250 mg twice daily. Eight-fold increases were seen in 2% of PAH patients on 125 mg twice daily and 7% of PAH patients on 250 mg twice daily.

Source: FDA prescribing information (DailyMed). Set ID: 8444da17-6c31-492b-8842-93740f083d9d. SPL document ID: 6f108d08-40d2-4db6-a938-f6c3b54b3e02. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Bosentan (FDA label)

Cytochrome P450: Coadministration of bosentan with drugs metabolized by CYP2C9 and CYP3A can increase exposure to bosentan and/or the coadministered drug ( 4.2 , 4.3 , 7.1 ). Hormonal contraceptives: Bosentan use decreases contraceptive exposure and reduces effectiveness ( 7.2 ). 7.1 Cytochrome P450 Drug Interactions Bosentan is metabolized by CYP2C9 and CYP3A. Inhibition of these enzymes may increase the plasma concentration of bosentan [see Clinical Pharmacology ( 12.3 )] . Concomitant administration of both a CYP2C9 inhibitor (such as fluconazole or amiodarone) and a strong CYP3A inhibitor (e.g. ketoconazole, itraconazole) or a moderate CYP3A inhibitor (e.g. amprenavir, erythromycin, fluconazole, diltiazem) with bosentan will likely lead to large increases in plasma concentrations of bosentan. Coadministration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with bosentan is not recommended.

Source: FDA prescribing information (DailyMed). Set ID: 8444da17-6c31-492b-8842-93740f083d9d. SPL document ID: 6f108d08-40d2-4db6-a938-f6c3b54b3e02. Label effective date: June 2, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.